Skip to search formSkip to main contentSkip to account menu

VLP-encapsulated TLR9 Agonist CMP-001

Known as: CMP-001 
An agent composed of an unmethylated CpG motif-rich G10 oligonucleotide, which is an agonist of toll-like receptor 9 (TLR9), encapsulated in… 
National Institutes of Health

Related topics

Related topics

2 relations
CYT 003NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
TLR9 Agonist May Reverse Resistance to Immune Checkpoint Inhibition in Melanoma
Treatment with the TLR9 agonist CMP-001 appeared to potentially reverse resistance to immune checkpoint inhibition in patients… 
2017
2017
Abstract 2669: Antitumor activity of the CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models
Targeted blockade of checkpoint inhibitors such as CTLA-4 or PD-1 with antagonist monoclonal antibodies (mAbs) has shown… 
2016
2016
Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma.
TPS9593Background: We are developing CMP-001 to facilitate activation of the innate immune response within a tumor that will… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)